ANTI-IDIOTYPE ANTIBODY APPROACH FOR AN HIV VACCINE
ANTI-IDIOTYPE ANTIBODY APPROACH FOR AN HIV VACCINE
批准号:
3489461
负责人:
CHANG-YUIL KANG
金额:
$5.0万
依托单位国家:
美国
项目类别:
财政年份:
1991
资助国家:
美国
项目状态:
已结题
起止时间:
1991-08-15 至 1992-02-14
关键词:
AIDS vaccines Anthropoidea B lymphocyte HIV envelope protein gp120 antibody neutralization test antiidiotype antibody antiserum antiviral antibody enzyme linked immunosorbent assay human immunodeficiency virus human tissue immunoregulation laboratory mouse neutralizing antibody protein purification technology /technique development
中文摘要
描述:(改编自申请人的摘要)试图做一个
英文摘要
DESCRIPTION: (Adapted from the applicant's abstract) Attempts to make a
practical HIV vaccine have been unsuccessful to date. The applicant
proposes using anti-idiotype antibody (anti-id) as an HIV vaccine to elicit
high titers of group-specific neutralizing antibodies. The principle of
this approach is based on idiotype matching, which utilizes anti-ids as
surrogates for antigen in an attempt to stimulate specific elements of the
B cell repertoire in humans. The applicant will generate and characterize
a panel of murine anti-id Mabs against human polyclonal anti-gp120
antibodies. The characterization of anti-id Mabs will be achieved by
affinity isolation with individual anti-id Mabs which interact with group
specific neutralizing anti-gp120 antibodies for further studies in
primates. To identify anti-id Mabs of potential utility in eliciting
group-specific neutralizing antibodies, monkeys will be immunized with
anti-id Mabs and the sera will be evaluated for neutralizing anti-gp120
antibodies. Evaluation of neutralizing antibodies will be done by
measurement of anti-gp120 titer in ELISA and virus neutralization assay
using various HIV isolates. In Phase II, protection experiments against
viral infection in primates and further evaluation of anti-id Mabs as an
HIV vaccine in humans, will be performed.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120.
鉴定出受 CD4 与 gp120 附着影响的新中和表位构象。
DOI:
--
发表时间:
1993
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Kang,CY, Hariharan,K, Posner,MR, Nara,P]
通讯作者:
Nara,P
Anti-idiotype monoclonal antibody elicits broadly neutralizing anti-gp120 antibodies in monkeys.
抗独特型单克隆抗体在猴子体内引发广泛中和抗 gp120 抗体。
DOI:
10.1073/pnas.89.7.2546
发表时间:
1992
期刊:
Proceedings of the National Academy of Sciences of the United States of America
影响因子:
11.1
作者:
[Kang,CY, Nara,P, Chamat,S, Caralli,V, Chen,A, Nguyen,ML, Yoshiyama,H, Morrow,WJ, Ho,DD, Köhler,H]
通讯作者:
Köhler,H
Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals.
对 HIV 感染者中糖蛋白 120 中和表位特异的 B 细胞库进行分析。
DOI:
10.1089/aid.1994.10.1629
发表时间:
1994
期刊:
AIDS research and human retroviruses
影响因子:
1.5
作者:
[Hariharan,K, Nara,PL, Shabazz,LA, McCutchan,JA, Kang,CY]
通讯作者:
Kang,CY
Two major groups of neutralizing anti-gp120 antibodies exist in HIV-infected individuals. Evidence for epitope diversity around the CD4 attachment site.
HIV 感染者体内存在两大类中和性抗 gp120 抗体。
DOI:
--
发表时间:
1992
期刊:
Journal of immunology (Baltimore, Md. : 1950)
影响因子:
--
作者:
[Chamat,S, Nara,P, Berquist,L, Whalley,A, Morrow,WJ, Köhler,H, Kang,CY]
通讯作者:
Kang,CY
Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals.
人类免疫缺陷病毒感染的无症状个体中交叉反应性抗 gp120 抗体群体的分析。
DOI:
10.1128/jvi.67.2.953-960.1993
发表时间:
1993
期刊:
Journal of virology
影响因子:
5.4
作者:
[Hariharan,K, Nara,PL, Caralli,VM, Norton,FL, Haigwood,N, Kang,CY]
通讯作者:
Kang,CY
ANTI-IDIOTYPE ANTIBODY APPROACH FOR AN HIV VACCINE
-
批准号:3506178
-
项目类别:
-
资助金额:$25.0万
-
财政年份:1991
-
负责人:CHANG-YUIL KANG
-
依托单位:
ANTI-CD4 ANTIBODY AS THERAPEUTIC/PREVENTIVE HIV VACCINE
-
批准号:3489229
-
项目类别:
-
资助金额:$5.0万
-
财政年份:1990
-
负责人:CHANG-YUIL KANG
-
依托单位:
海外基金